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Abstract: Cardiovascular disease (CVD) is currently the leading cause of death in the 
United States [1]. One of the key factors in CVD development is cholesterol levels; 
accumulation of cholesterol in the macrophage has been linked to plaque formation and 
subsequent heart attack or stroke [3]. ATP-binding cassette transporter A1 (ABCA1) is 
the protein that facilitates cholesterol efflux out of the macrophage, and increasing this 
efflux can prevent the macrophage from being a pro-atherogenic foam cell. In addition, 
garlic-derived organosulfur compounds have been suggested to have cholesterol-lowering 
effects [35]. The aim of this study was to investigate the effects in mouse macrophages of 
garlic compounds diallyl disulfide (DADS), allyl mercaptan (AM), and S-allyl-L-cysteine 
(SAC) on ABCA1 expression compared with trichostatin A (TSA), a drug known to 
induce ABCA1 via histone modification. RAW 264.7 cells were treated with these 
compounds for six hours, and RNA was isolated, reverse transcribed, and analyzed for 
changes in gene expression. ABCA1 expression was induced with DADS, AM, and SAC, 
but no change was seen in expression of ATP-binding cassette transporter G1 (ABCG1) 
or HMG Co-A Reductase (HMGCR). Chromatin immunoprecipitation assays showed no 
significant differences in acetylated histone H3 or H4 in the promoter of ABCA1 due to 
treatment with DADS. Luciferase reporter assays revealed garlic-induced ABCA1 
promoter activation with fragments as short as 75 bp upstream of the transcriptional start 
site and up to 2500 bp, suggesting the transcriptional upregulation may not be due to 
histone modification in the promoter. These results show that ABCA1 mRNA is 
significantly increased by treatment with DADS, SAC, and AM, and this effect may or 
may not be mediated by histone modification. Additional studies are required to 
understand the mechanisms underlying this effect. 
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CHAPTER I 
 
 
INTRODUCTION 
Over the last several decades, America has seen a significant shift in patterns of 
diet and physical activity. Changes such as increasing consumption of a high-fat, high-
sugar diet and decreasing levels of physical activity have driven an increase in prevalence 
of metabolic disorders such as cardiovascular disease, obesity, and diabetes. 
Cardiovascular disease (CVD) is currently the leading cause of death in the United States 
[1]. Oklahoma is no exception to this trend; 10,000 Oklahomans died in 2014 due to 
CVD alone [2]. Due to these trends, prevention and treatment of CVD have become a 
priority in national health. In the interest of using lifestyle approaches to treat CVD, 
functional properties of foods such as fruits and vegetables are being explored in hopes of 
finding new strategies to reduce the impact of this disease. 
Serum cholesterol levels are a main target of CVD treatment due to the potential 
of this cholesterol to be transported into the macrophage and accumulate. This buildup 
can eventually lead to plaque formation and subsequent heart attack or stroke. High 
density lipoprotein (HDL), known as the “good cholesterol,” is involved in the reverse 
export of cholesterol from macrophages back to the liver, potentially reversing the 
buildup of cholesterol and slowing CVD development. ATP-binding cassette transporter 
A1 (ABCA1), a membrane-bound protein in macrophages, facilitates this process, along 
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with its partner ABCG1. Increasing ABCA1 and ABCG1 abundance is a potential 
strategy for lowering cholesterol levels as a complement to current cholesterol-lowering 
medications [14], which target the cholesterol synthesis pathway but may also have 
undesirable side effects such as increasing risk of developing type 2 diabetes [22]. 
Garlic, or Allium sativum, has long been claimed to possess extensive health 
benefits including immune boosting, antioxidant, antidiabetic, and hepatoprotective [26]. 
Consumption of a garlic supplement in various forms for at least two months in 
individuals with elevated total cholesterol >200 mg/dL was associated with an 8% 
reduction in total cholesterol with only a slight improvement in serum HDL and no effect 
on triglyceride levels [35]. This study demonstrates the potential of garlic to be part of the 
therapeutic strategy for treating high cholesterol. More specifically, the organosulfur 
compounds that make up 2.3% of raw garlic are potentially bioactive. Compounds of 
interest include diallyl disulfide (DADS), allyl mercaptan (AM), and S-allyl-L-cysteine 
(SAC).  
Research in the cancer field has suggested that these compounds may work by 
inhibition of histone deacetylases (HDAC) [46-48]. HDACs work to deacetylate histone 
proteins in the scaffolding of nuclear DNA, typically leading to a decrease in 
transcription due to a tighter chromatin structure. Thus, an HDAC inhibitor (HDACi) can 
lead to an increase in transcription by allowing the chromatin to remain open. Garlic-
derived compounds have been shown to have HDACi function in affecting genes related 
to cancer. 
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Objective:  The present study was undertaken to investigate the effects of garlic-derived 
compounds on CVD-related genes and possible mechanisms for these effects.  
Hypothesis: Garlic-derived compounds DADS, AM, and SAC increase mRNA 
expression of ABCA1 in macrophages, and may be exerting this effect by working as 
HDACi that modify histones in the promoter region of ABCA1.  
Aim 1: To distinguish the effects of garlic-derived compounds on transcription 
regulation of genes ABCA1 and ABCG1. 
Aim 2: To explore the role of garlic-derived compounds in chromatin remodeling 
in the promoter region of ABCA1 via HDAC inhibition. 
Aim 3: To characterize the specific region of the ABCA1 promoter that is 
activated in response to garlic-derived compound treatment. 
This work was supported in part by funding from the United States Department of 
Agriculture, Project OKL02991 (S.L.C.) 
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
CVD pathophysiology  
CVD can occur as a result of atherosclerosis, a condition in which plaque 
formation in blood vessel walls leads to blockages and subsequent strokes and/or heart 
attacks. Atherosclerosis is defined broadly as a “response to injury” [3]. This injury 
occurs in a blood vessel wall in response to a variety of factors, including high blood 
pressure, smoking, diabetes, and elevated blood lipid levels. These factors can cause 
arterial endothelial cells to express adhesion molecules that then retain monocytes 
streaming through the blood. Once inside the artery wall, the monocytes differentiate into 
macrophages. As the endothelium becomes increasingly permeable, cholesterol-rich low 
density lipoprotein (LDL) particles can also enter and be phagocytosed by macrophages. 
Cholesterol-rich macrophages are termed “foam cells.” Other changes in the arterial wall 
include the uptake of smooth muscle cells (SMCs), increased synthesis of proteins such 
as collagen, and cytokine secretion [4]. Foam cells and SMCs can die, causing a buildup 
in a central lipid core, or plaque region. Eventually this plaque can rupture, leading to the 
attraction of platelets and other coagulation factors, and blockage of blood flow can cause 
a heart attack or stroke. 
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Lipids and cholesterol play a significant role in disease development, and are 
transported through the blood bound to lipoproteins. Low density lipoprotein (LDL) 
transports lipids and cholesterol from the liver to the rest of the body and can be found 
circulating in the blood at varying levels. CVD has been associated with elevated levels 
of circulating cholesterol and LDL [5], and one cell type affected by these high levels is 
the macrophage. While the macrophage is normally thought of in terms of immunity due 
to its role in phagocytosing foreign invaders and protecting the body, it also has the 
ability to take in large amounts of cholesterol bound to LDL. When a macrophage takes 
up more cholesterol than it can efflux to HDL, cholesterol is stored in the cytoplasm in 
the form of cholesteryl ester. Accumulating levels of cytoplasmic cholesterol turn 
macrophages into foam cells, which then and contribute to the buildup of plaque in 
atherosclerotic lesion. Uptake of oxidized LDL causes macrophages to produce pro-
inflammatory signaling molecules, or cytokines, which speed the development of 
atherosclerosis [6]. Thus, controlling blood lipid and cholesterol levels through dietary 
and other therapeutic interventions is a significant regulatory action in preventing the 
development of CVD. Indeed, a meta-analysis of 38 relevant studies showed that a 10% 
reduction in serum cholesterol can reduce CVD risk by as much as 54% [7]. 
Another lipoprotein, high density lipoprotein (HDL), performs an action known as 
reverse cholesterol transport (RCT), in which cholesterol is transported from peripheral 
cells back to the liver [8]. Here, it contributes to a pool of cholesterol that can be used to 
synthesize new bile acids. Through the efflux process, cholesterol levels in peripheral 
cells, specifically macrophages, can be decreased. Dysfunction of this process can 
contribute to atherosclerotic foam cell development. Low serum HDL has been 
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implicated in CVD development [9], although it remains to be determined whether this is 
a correlation or causality. In addition to testing serum HDL, recent studies have also 
begun to explore the cholesterol efflux capacity of HDL [6]. A longitudinal study 
following a large group cohort of initially healthy adults for nine years found that 
lowered cholesterol efflux capacity, as evidenced by plasma uptake of fluorescence-
labeled cholesterol, was positively associated with incidence of cardiovascular disease 
[10]. These results suggest that increasing the capacity of the macrophage to efflux 
cholesterol to HDL may reduce CVD risk. 
ABCA1 in reverse cholesterol transport 
ATP-binding cassette transporter A1 (ABCA1) is the membrane-bound protein 
that facilitates reverse cholesterol efflux in peripheral cells, specifically macrophages 
[11]. ABCA1 binds to the circulating lipoprotein apoA-1 (also known as pre--HDL) and 
facilitates transport of unesterified cholesterol from the macrophage to apoA-1. After 
receiving this cholesterol, apoA-1 becomes an HDL particle. Alternate efflux pathways 
involve ATP-binding cassette transporter G1 (ABCG1) and scavenger receptor B type I 
(SR-BI), which both efflux cholesterol to mature HDL particles. HDL carries this 
cholesterol to the liver, where a hepatic form of SR-BI takes up the cholesterol. In the 
liver, the cholesterol can be incorporated into bile acids [12].  
Mutations in ABCA1 are known to cause Tangier disease, where a virtual absence 
of HDL leads to an accumulation of cholesterol and subsequent hepatosplenomegaly, 
peripheral neuropathy, and increased CVD risk [13]. Increased ABCA1 expression can 
lead to increased RCT, a process that can prevent macrophages from becoming pro-
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atherogenic foam cells. Indeed, overexpression of ABCA1 in LDL-receptor knockout 
mice was shown to inhibit atherosclerotic lesion progression [14]. The half-life of 
ABCA1 mRNA and protein is relatively short (no longer than four hours), signifying the 
efflux process is quickly responsive to changes in signaling [15]. Thus, ABCA1 is a 
significant control point in overall cholesterol metabolism. Importantly, portions of the 
ABCA1 promoter region are conserved between humans and mice (Figure 1).  
The most well-characterized form of ABCA1 regulation is the LXR pathway. 
LXR, or liver X receptor, is a nuclear nutrient sensor present throughout the body in two 
isoforms: LXRα and LXRβ. LXRα is expressed in the liver, kidney, intestine, and 
macrophage; LXRβ is ubiquitously expressed [16].  Oxysterol, an oxidized derivative of 
cholesterol, is ligand that activates LXRs. When cellular cholesterol levels are high, 
oxysterol binds to LXR, which then binds to its heterodimer, retinoid X receptor (RXR). 
This complex binds to the ABCA1 promoter to increase transcription and promote 
cholesterol efflux. Through this signaling system, LXR acts to counteract higher cell 
cholesterol levels. Thus, LXR agonists have been a suggested therapeutic drug for 
increasing RCT and treating CVD. However, the LXR signaling pathway also triggers an 
increase in lipid synthesis and higher plasma triglycerides [17], which would be 
counterproductive for patients with pre-existing hyperlipidemia.   
The LXR binding region is located 50 bp upstream from the ABCA1 
transcriptional start site (Figure 1). Other important binding factors in the ABCA1 
promoter include specificity protein 1 (Sp1, -100 and -166 bp), and activator protein 1 
(AP-1, -131 bp). Sp1 is a ubiquitously expressed transcription factor known to affect cell 
cycle regulation genes, housekeeping genes, and tissue-specific genes. A variety of  
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Figure 1.  
mABCA1 CTCTGTCT-CAATTAAAACAAATAAAATAGAGGCAGAAAAACTTTATCTAA---CTTTGG -969 
       ::::: :: :: :: :  :::::         : : : :::::  ::  ::   :: ::   
hABCA1 CTCTGGCTGCACTTCA--CAAAT---------GTATACAAACTAAATACAAGTCCTGTGT  
mABCA1 TCGTTTGACA-------TCATCAAAACCCACTCTTGTGACCACAGCTGCCCCTTGTGGCT -909 
       :  : : :::       : ::::: :     :  ::  :  : :   :        ::::  
hABCA1 TTTTATCACAGGGAGGCTGATCAATA-----TAATGAAATTAAAAGGG--------GGCT  
mABCA1 TATAGGTACCTATTACTAGTGGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTAGAAGGT -849 
           ::: : ::::    ::   :::: : ::: ::: ::: : : : : :::      :  
hABCA1 ----GGTCCATATT----GTTCTGTGTTTTTGTTTGTTTGTTTCTTTTTTTGTT---TTT  
mABCA1 GCAGACTAGGTCCCTGGAAGGTGTGT-GTGTGTGTGTGTG-TGTGTGTGTGTGTGTGTGT -789 
       :  : ::   :::    ::  : ::  : :     ::  : :::   : :  :    : :  
hABCA1 GTGGCCTCCTTCCTCTCAATTTATGAAGAGAAGCAGTAAGATGTTCCTCTCGGGTCCTCT  
mABCA1 GTGTGTGTGTAGAAGGTGCAGACTAGGTCCCTGGAAGGTAG-AGATCTTCTCTTCAAAAT -729 
       : : :      : :: : ::: :: ::   ::  :::: :: :: ::  :: :  :::::  
hABCA1 GAGGGACCTGGGGAGCT-CAGGCTGGGAATCTCCAAGGCAGTAGGTCGCCTATCAAAAAT  
mABCA1 CAATGTAAAGGTTTGAGGCAG--ACACCAAAATAGGCTGATATTCACTGTCCATTCCACA -669 
       ::: ::  ::::::: ::  :  : :: :::  :: :   ::  ::  :  :  ::: :   
hABCA1 CAAAGTCCAGGTTTGTGGGGGGAAAACAAAAGCAGCCCATTACCCAGAGGACTGTCCGCC  
mABCA1 T--CCCTTCCCCCAATCTAGGACTTTTAAAGGAAGAAAAGGAAGAGACCGAAAATGGTTG -609 
       :  ::::  :::::  ::::: :::: :::::::  ::: ::  ::::  :::::: :::  
hABCA1 TTCCCCTCACCCCAGCCTAGGCCTTTGAAAGGAAACAAAAGACAAGAC--AAAATGATTG  
mABCA1 GCATCTGGGGGTGGGGTGGGGTGGGGAGTTTTC-CTTCCCAAGTTGGG------GGCTGA -549 
       :: ::  : :: : : :   :    ::: : :: :: ::: : :          ::::::  
hABCA1 GCGTCCTGAGG-GAGATTCAGCCTAGAGCTCTCTCTCCCCCAATCCCTCCCTCCGGCTGA  
mABCA1 GCAAACTAACAAAAGGAGAGGGGGGAGAGTGGGAGTAAGGGAGAGCGGGAGGGAGAGAGG -489 
       : :::::::::::                                             ::  
hABCA1 GGAAACTAACAAA---------------------------------------------GG  
mABCA1 AAGAGGGCATACACACACAAACAAAACAAACAAAACTCAAAAAGCAACACCCACAAAACC -429 
       ::                                    :::::                   
hABCA1 AA------------------------------------AAAAA-----------------  
mABCA1 CCAAACAATTGCAGAAAG-AGGAGTTTAGAGAACGAGCTT-TTCCCCTTTCCTCCT---C -369 
             :::::: ::::: :::: ::::::: :  :::   :::: ::     :::   :  
hABCA1 ------AATTGCGGAAAGCAGGA-TTTAGAGGA--AGCAAATTCCACTGGTGCCCTTGGC  
mABCA1 TGCCGGGAATGTGGA-------GTCCCTGGCTCAGCGCA-AGTCCGGAGTTTCCCGTTTC -309 
       ::::::::: :::::       :::   ::: :::: :  :: :: : : ::::::      
hABCA1 TGCCGGGAACGTGGACTAGAGAGTCTGCGGCGCAGCCCCGAGCCCAGCGCTTCCCGCGCG  
mABCA1 CCGAAGGCTAGCAGGTCAGGGCCAGGGCTA------CAGAAAGCGGGCCCCACAAA---- -249 
        :  ::::  :: :: : ::::  :::         ::::  :::: ::: :  :       
hABCA1 TCTTAGGCCGGCGGGCCCGGGCGGGGGAAGGGGACGCAGACCGCGGACCCTAAGACACCT  
mABCA1 GCTCTCACCATGCGCCCCCAG----------TGCCCGCTGC-----------------GG -189 
       ::: : ::: : : ::::::           : ::: :  :                 ::  
hABCA1 GCTGT-ACCCTCCACCCCCACCCCACCCACCTCCCCCCAACTCCCTAGATGTGTCGTGGG  
mABCA1 CGGCGCACTGTCGCCGGTTTAAGGGGCGGGCCATGTCTCCACGTGCTTTCTGCTGAGTGA -129 
       ::::  :  :::::: ::::     Sp1       : :::::::::::::::::: AP-1aa          
hABCA1 CGGCTGAACGTCGCCCGTTTAAGGGGCGGGCCCCGGCTCCACGTGCTTTCTGCTGAGTGA  
mABCA1 CTGAACTACATAAACAGAGGCCGGGAAGGGGGCGGGGGAAAGAGGGAGAGAACAGCGTTT -69 
         AP-1::::::::::::::::::::::     Sp1     : ::::::::: ::::  :::  
hABCA1 CTGAACTACATAAACAGAGGCCGGGAACGGGGCGGGG--AGGAGGGAGAGCACAGGCTTT  
mABCA1 GACCGGTAGTAACCCCGGCGCTCGGCACAGCCGAATCTATAAAAGGAACTAGTCGCGGCA -9 
       ::::: ::::LXRE    :::::::::  ::::::::::TATA box ::::::::: :::::  
hABCA1 GACCGATAGTAACCTCTGCGCTCGGTGCAGCCGAATCTATAAAAGGAACTAGTCCCGGCA  
mABCA1 AAAACCA-GTAATTCCGAGGGCGAGCGAGCGGG-CCGGGACCGGCAGAGCCCA------- 52 
       ::::::  :::::: :::: : ::: ::: ::: :::::::: :::::::: :         
hABCA1 AAAACCCCGTAATTGCGAGCGAGAGTGAGTGGGGCCGGGACCCGCAGAGCCGAGCCGACC  
mABCA1 CTTCTCTCCGCGGCGCAGCG-CAAAGCTGGGCAGGGGGCGCCGCGGGACCCGCGCAACCA 112 
       ::::::::: ::: :: ::: ::  :: :::: ::: :: :::::       : : : ::  
hABCA1 CTTCTCTCC-CGG-GCTGCGGCAGGGCAGGGCGGGGAGCTCCGCG-------CACCAACA  
mABCA1 CAGCCGGCTTGGGGAGCTGCTCTGCTCCCTGTTTCCCCCCA----CTTTTTTCTTCCCCT 172 
        :::::: :    : :: ::: :::::: :::::   :::     :: :::::: ::: :  
hABCA1 GAGCCGGTTCTCAGGGC-GCTTTGCTCCTTGTTTTTTCCCCGGTTCTGTTTTCTCCCCTT  
mABCA1 TTCTGGAAGGGTTTGTGCAGGGGTAGGGAAAACAGACTCAAACAGCAAA 221 
        :: :::::: :: ::  :::::::::  ::: :::: ::::::  :::  
 
hABCA1 CTCCGGAAGGCTT-GTCAAGGGGTAGGAGAAAGAGACGCAAACACAAAA  
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Figure 1: Comparison of the mouse and human ABCA1 promoter sequences. 
BLAST and LAlign software were used to align homologous sequences (connected by a 
colon) in the 5’ flanking region of the ABCA1 gene, from -2500 bp to +300 bp. Analysis 
revealed a 189 bp sequence (boxed) with 90% similarity in the region immediately 
preceding the conserved transcriptional start site of ABCA1, which suggests a conserved 
promoter for ABCA1 exists in this region [18 ]. Other conserved regions include the 
TATA box (-35 bp), LXRE (-53 bp), Sp1 (-100 and -166 bp), and AP-1 (-131 bp). The 
transcriptional start site and first exon of ABCA1 are highlighted. 
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proteins interact with Sp1 to either increase or decrease transcription, including estrogen 
receptor proteins (increase) and p53 (decrease) [19], and aberrant Sp1 function has been 
implicated in cancers and neurodegenerative diseases. Sp1 binding to the ABCA1 
promoter was found to be essential for LDL-induced upregulation of ABCA1 expression 
[16]. Similarly, AP-1 is a transcription factor linked to cellular proliferation and 
apoptosis, and its control of expression of cytokines such as tumor necrosis factor alpha 
and interleukin 1 implicate it in progression of immune disorders and cancers [20]. No 
studies to date have documented a role of AP-1 in ABCA1 regulation. 
Prevention of CVD  
Due to the importance of blood lipid levels in CVD, many drug therapies for 
CVD involve lipid-lowering medications. The main class of these drugs is termed 
“statins,” which act by inhibiting key enzymes in the cholesterol biosynthesis pathway 
(namely 3-hydroxy-3-methylglutaryl-CoA reductase, or HMGCR). However, use of 
statins has been linked to complications such as muscle weakness and damage, peripheral 
neuropathy, and an elevated risk of developing type 2 diabetes [21, 22].  Due to these 
risks, alternative approaches to treating and preventing CVD must be explored.  
Research has linked the prevention of CVD to several key lifestyle factors, 
including avoidance of smoking, regular physical activity, normal body mass index, and 
eating a balanced diet [23]. Dietary recommendations include limiting intake of trans fats 
and saturated fats, sugar-sweetened beverages, and refined carbohydrates, and increasing 
consumption of fruits, vegetables, whole grains, and unsaturated fats. The popular 
Dietary Approaches to Stop Hypertension (DASH) Diet advocates these 
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recommendations along with limiting sodium intake [24], and adherence to this diet has 
been shown to significantly reduce CVD risk [25]. 
Increasing consumption of “whole foods” (fruits, vegetables, whole grains, nuts, 
and legumes) as an approach to reduce risk of CVD is an attractive alternative to drug 
therapies due to its accessibility to the general public and lack of dangerous side effects. 
One such food, garlic, has received recent attention for its role in reducing CVD risk. 
Garlic 
Garlic (Allium sativum) is a food belonging to the onion genus and has long been 
touted for its potential to prevent disease. As long as 3,500 years ago, an Egyptian 
medicinal guide advocated consumption of garlic to treat heart disorders, tumors, and 
worms [26].  Anecdotal evidence promoting garlic’s health benefits has accumulated over 
the years, and through scientific research it has become clear that the bioactive sulfur-
containing compounds in garlic drive these benefits.  
Garlic naturally contains 2.3% organosulfur compounds, which create its 
distinctive odor and taste; however, these compounds are volatile and can change forms 
(Figure 2). In an intact garlic bulb, the major sulfur-containing compounds are γ-
glutamyl-S-allyl-L-cysteine and S-allyl-L-cysteine sulfoxides, or alliin [27]. Alliin is 
converted into thiosulfinates such as allicin through enzymatic action when the garlic 
bulb is crushed or cut (Figure 2). γ-Glutamyl-S-allyl-L-cysteine, on the other hand, is 
converted into S-allyl-L-cysteine (SAC) when an aqueous solution is used to extract 
garlic [27]. 
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The compound allicin is not absorbed by the human body [28] and has been found 
to be unstable: after 20 hours at 20°C, it completely degraded into diallyl disulfide 
(DADS) (66%), diallyl sulfide (DAS) (14%), and diallyl trisulfide (DATS) (9%) [29]. It 
is believed that stomach acid degrades allicin to these compounds that may then be 
absorbed by humans and animals. Once absorbed, DADS circulates in the body along 
with its major metabolite, allyl mercaptan (AM); in rat liver cells DADS was converted 
to AM within 30 minutes after ingestion [30]. Indeed, after ingestion of grated garlic, a 
breath test administered to human subjects showed two major peaks identified as AM and 
DADS [31].   
Preparation of garlic can greatly affect the composition of bioactive components, 
making it difficult to elucidate the effects of single compounds in studies involving 
animal or human dietary interventions. Garlic powder, garlic oil, and aged garlic extract 
(AGE) are commonly used preparations. Garlic powder and garlic oil contain oil-soluble 
sulfur compounds such as DADS and DATS [27]. Aged garlic extract (AGE) refers to 
sliced raw garlic stored in alcohol for 15-20 months, which creates an overall loss of 
allicin and high levels of SAC [32], which can be absorbed by the human body [33]. 
The roles of these bioactive components in health are being actively explored in 
both humans and animals. Suggested physiological roles include antioxidant, immune 
boosting, antimicrobial, antidiabetic, hepatoprotective, and anti-platelet aggregatory [25], 
but arguably the most interest has been in the realms of cancer and CVD. 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Garlic compound structures and decomposition pathways. γ-glutamyl-S-
allyl-L-cysteine and S-allyl-L-cysteine sulfoxides (alliin) are present in raw, intact garlic 
[34]. Alliin is converted to allicin when the bulb is crushed or cut, but quickly 
decomposes to DADS. In the body, DADS can be metabolized to AM. γ-Glutamyl-S-
allyl-L-cysteine is converted into S-allyl-L-cysteine (SAC) in aqueous garlic extracts.  
S-allyl-L-cysteine 
sulfoxide (Alliin)  
Allicin  
Raw garlic: 
Diallyl disulfide 
(DADS) 
Allyl mercaptan 
(AM) 
γ-Glutamyl-S-allyl-L-cysteine  + 
S-allyl-L-
cysteine (SAC) 
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Garlic in promoting RCT/decreasing cholesterol synthesis 
Much research has been done in regards to garlic’s effect on CVD related to 
serum lipids. A recent meta-analysis of 39 trials testing the effect of garlic on total 
cholesterol, LDL, HDL, and triglycerides [35] found an overall 8% reduction in total 
cholesterol related to garlic treatment, which is associated with a 38% decrease in risk of 
a coronary event [7]. Garlic was also found to moderately lower LDL and raise HDL, and 
Reid suggests that although the cholesterol-lowering effects of garlic may be modest, the 
absence of serious side effects related to this treatment makes garlic a viable alternative 
to traditional cholesterol-lowering medications [35].  
Although a sizeable amount of research has been done on the correlation between 
garlic treatment and cardiovascular outcomes including serum lipoprotein levels [33-36], 
research is less abundant in regards to the mechanism of action. Cho et al. [36] found that 
allyl mercaptan (AM) decreased cholesterol synthesis and secretion in human Hep-G2 
cells, as evidenced by levels of radiolabeled [3H] acetate incorporation into cholesterol 
and subsequent secretion into media. This suggests garlic compounds may help by 
reducing overall cholesterol synthesis. Lee et al. [37] found that rats supplemented with a 
garlic extract on a high-fat diet had higher serum HDL cholesterol related to increased 
gene expression of apolipoprotein A-I. While both are viable pathways, limited research 
suggests that garlic might also work to improve cardiovascular outcomes by increasing 
reverse cholesterol transport through the ABCA1 transporter. Malekpour et al. [38] found 
that human THP-1 macrophages treated with SAC had increased mRNA expression of 
ABCA1.  
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Epigenetic modification & histone remodeling 
While one line of our research involves looking at changes in gene expression due 
to garlic compound treatment, a deeper question involves the molecular mechanism by 
which these changes occur. A feasible explanation is that garlic works through epigenetic 
modification. “Epigenetics” refers to alterations of gene expression that leave the actual 
DNA sequence unchanged. Excitement related to the field of epigenetics has risen as 
research unfolds because epigenetic abnormalities are much more modifiable than genetic 
abnormalities. Treatments for chronic diseases that target gene expression via epigenetic 
mechanisms are more attractive than altering the actual DNA sequence; the same effect 
can be accomplished by “silencing” a gene rather than permanently modifying it.  
One pathway to epigenetic modification involves a class of regulatory proteins 
known as histones. Histone proteins act as a scaffolding around which double-stranded 
DNA is wrapped within the chromosome structure. In the past it was thought that 
histones played only a structural role, but more recent research shows that modification to 
histones can have a dramatic effect on DNA transcription [39]. These modifications are 
not permanent, so genes can be alternatively activated or repressed depending on the 
system doing the modifications [46]. The most significant way histones can be modified 
is acetylation/deacetylation, which involves the “relaxing” of the DNA wound around the 
histone. This in turn can cause increased transcription. When the acetyl group is removed, 
the DNA is wound more tightly and is less accessible to transcription enzymes.  
The modifications to histones are temporary, and enzymes are required to 
maintain them. Histone acetyltransferases (HATs) transfer acetyl groups to the histones; 
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histone deacetylases (HDACs) remove these groups. The action of HDACs is correlated 
with a transcriptional repression due to the tighter chromatin structure. Eighteen known 
HDACs exist in mammals and are divided into four classes. Class I and II (HDACs 1-10) 
are associated with adaptive immunity, and functions include growth and development, 
immune/inflammatory response, and endothelial integrity [46]. Class III (HDACs 12-18) 
are known as SIRTs and act in the mitochondria via NAD+-dependent deacetylation; 
functions include cellular aging, transcription, DNA repair, and apoptosis [46]. Class IV 
includes only HDAC 11, and dysregulation is associated with gene variants (rather than 
overexpression) in multiple sclerosis [40]. 
HDACs naturally function to regulate many cellular processes, including 
adipogenesis, lipid metabolism, myogenesis, and gluconeogenesis. In a healthy 
individual, HDACs inactivate genes at appropriate times. For example, HDAC3 works to 
repress lipid oxidation during the fed state [41]. However, HDAC dysfunction has been 
implicated in the pathogenesis of various diseases including cancer [46]. Overexpression 
of HDAC may lead to lower transcription of tumor suppressor genes and contribute to the 
advancement of the disease. HDAC activity has been linked to progression of cancers 
such as prostate, gastric, and colorectal [42, 43, 34]. HDAC3 and 7 are associated with 
inflammatory gene expression and pro-inflammatory activation of macrophages [44, 45], 
and HDAC9 deletion in LDLr-/- mice led to a decrease in atherosclerotic lesion size, 
enhanced macrophage cholesterol efflux, and a reduction in total and LDL cholesterol 
[66]. 
Due to the potentially harmful effects of some HDACs, compounds that have an 
inhibitory effect on HDACs (called HDAC inhibitors, or HDACi) are of interest. Both 
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synthetic and naturally occurring HDACi exist. A commonly used HDACi is trichostatin 
A (TSA), which is a naturally occurring microbial metabolite of Streptomyces 
hygroscopicus [46]. TSA is a pan-HDAC inhibitor and is extremely potent. The main 
effect of treatment with HDACi is a de-repression of transcription, leading to increased 
gene expression. HDACi have been suggested to reactivate genes normally silenced in 
cancer cells such as those involved in normal cell death; indeed, HDACi were shown to 
induce apoptosis in a range of cancer cells [46].  
The field of cancer research offers valuable insight into the possible mechanism 
behind the effects of the bioactive components of garlic. Nian et al. [47] showed that 
treatment of human HT-29 colon adenocarcinoma cells with garlic compound allyl 
mercaptan (AM) inhibits activity of HDAC and increases histone acetylation, specifically 
in the promoter region of P21WAF1, a gene related to cell cycle control. Levels of Sp3, a 
transcription factor for P21WAF1, are higher in AM-treated cells. This study suggests 
that AM works to increase expression of tumor suppressor genes via HDACi action. 
Druesne et al. [48] demonstrated that treatment with diallyl disulfide (DADS) has a 
similar effect in these cells; specifically, it induces histone hyperacetylation at histone 
H3, lysine residue 14. 
Extensive research has been conducted on bioactive compounds of garlic in genes 
related to cancer, but fewer investigations have been done regarding CVD. Thus, we 
proposed to explore the possible roles of garlic compounds in increasing expression of 
cholesterol efflux transporter ABCA1, as well as secondary efflux transporter ATP-
binding cassette transporter G1 (ABCG1) and HMG Co-A Reductase (HMGCR). A 
chromatin immunoprecipitation assay was also used to explore possible histone 
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modification in the ABCA1 promoter due to garlic compound treatment. Finally, we 
developed a gene construct system using a luciferase reporter assay to investigate what 
specific part of the ABCA1 promoter might be modified by garlic compound treatment, 
and whether this treatment could still modify transiently transfected plasmids not 
associated with chromatin structure.  
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CHAPTER III 
 
 
METHODOLOGY 
Maintenance of cells 
Murine macrophage RAW 264.7 cell line was obtained from a subclone of 
Abelson murine leukemia virus-induced tumor (ATCC; #TIB-71, Manassas, VA). RAW 
264.7 cells were maintained in complete media containing Dulbecco’s Modified Eagle’s 
Medium (DMEM) with 4.5g/L glucose, without L-glutamine, and with sodium pyruvate 
(VWR; Radnor, PA) supplemented with 10% fetal bovine serum (FBS) (Atlanta 
Biologicals; Flowery Branch, GA), 1% penicillin-streptomycin/L-glutamine (PS/L-glut) 
(Corning; Corning, NY). The cells were grown to 80% confluence in a 100-mm plate in 
10 mL of complete media and maintained at 37°C in a humidified incubator. Cells were 
passaged up to 20 times at a frequency of 48 hours at a 1:20 dilution. To determine the 
concentration of viable cells, cells were stained with 0.4% trypan blue (Corning) and 
counted under a microscope. Hepa 1-6 murine liver cells (ATCC, #CRL-1830), used for 
gene expression analysis in the liver, and HEK293T cells (ATCC, #CRL-11268), used 
for transfections, were maintained in an identical fashion. 
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Gene expression analysis 
RAW 264.7 murine macrophages were plated in 6-well plates at a density of 7.4 x 
105 cells per well in DMEM containing 10% FBS and 1% PS/L-glut for 18 hours prior to 
treatment. After 18 hours, cells were treated with either vehicle control (DMSO), 200 M 
DADS (Sigma, #2179-57-9), 900 M AM (Sigma, #870-23-5), or 2.5 mM SAC (TCI, 
#21593-771; Portland, OR) for six hours. Doses and treatment times were determined by 
reviewing relevant literature and conducting preliminary trials (data not shown). As a 
positive control, cells were also treated with the pan-HDAC inhibitor Trichostatin A 
(TSA) (Millipore Sigma; #647926; Darmstadt, Germany) at 0.03 M. Cells were treated 
for a total of six hours prior to extracting RNA for gene expression analyses or analysis 
of cell viability by the MTT assay. 
RNA Isolation, Reverse-Transcription and Gene Expression Analysis. At the end 
of the treatment period, total RNA was isolated using STAT-60 (Tel-Test, Inc.; 
Friendswood, TX), digested with DNase I (Roche Applied Science; Indianapolis, IN) and 
reverse-transcribed (Superscript II; Invitrogen; Carlsbad, CA). qPCR was performed 
using SYBR green (Applied Biosystems; Foster City, CA) chemistry on an ABI 7900HT. 
Data were analyzed by the 2-ΔΔCt method, with cyclophilin B as the invariant control. 
Table 1: Primer sequences for qPCR. 
Gene  GenBank 
reference 
Forward (5’-3’) Reverse (5’-3’) 
mABCA1 NM_013454 
 
CGTTTCCGGGAAGT
GTCCTA 
GCTAGAGATGACAAGGA
GGATGGA 
mCyclophilin NM_011149 
 
TGGAGAGCACCAAG
ACAGACA 
TGCCGGAGTCGACAATG
AT 
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mABCG1 NM_009593.1 
 
GCTGTGCGTTTTGTG
CTGTT 
TGCAGCTCCAATCAGTA
GTCCTAA 
mHMGCR BF464069 
 
CTTGTGGAATGCCTT
GTGATTG 
AGCCGAAGCAGCACATG
AT 
  
Cell viability 
MTT Assay. After 4 hours of treatment, MTT (Sigma) at 1 mg/mL final 
concentration was added to the media for an additional 2 hours. The media was removed 
and cells briefly washed, then treated with solubilization buffer (glycine).  The 
absorbance of the plate was read at 570 nm. Due to a decrease in cell viability associated 
with SAC treatment, no further assays were completed using SAC. 
Chromatin Immunoprecipitation:  
ChIP was performed using a SimpleChIP Enzymatic Chromatin IP Kit (Cell 
Signaling, #9003; Danvers, MA) following the manufacturer’s protocol. Because DADS 
is the most well-researched garlic-derived compound and most likely to function as an 
HDACi, ChIP was performed using only DADS and TSA as a positive control. Using the 
same dose (200 M DADS or 0.03 M TSA) and treatment time (six hours) as in gene 
expression analysis, 4x106 cells per treatment group were cross-linked  with 37% 
formaldehyde (VWR) for 10 minutes to preserve protein-DNA interactions. Cells were 
treated with micrococcal nuclease (included in kit) for 30 minutes to digest DNA to 
fragments of approximately 150-900 bp. Cells were then lysed using sonication (three 
sets of 20 second pulses on Fisher Scientific Sonic Dismembrator Model 100, level 5). 
Lysates were incubated with antibodies against acetylated histone H3 (Sigma, #06-599), 
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acetylated histone H4 (Sigma, #06-598), histone H3 (included in kit), and Rabbit IgG 
(included in kit). 10 L of sample was set aside before antibodies were added to use as an 
input control. Samples were incubated overnight at 4°C with primary antibody.  
After overnight incubation, Protein G Magnetic beads (included in kit) were 
added to each reaction and incubated to promote binding of the primary antibody to the 
beads. Using a magnetic rack (Cell Signaling), samples were washed to remove all 
unbound protein, and then washed again with an elution buffer to dissociate the DNA-
protein fragments from the beads. Cross-links were reversed by adding NaCl and 
proteinase K (included in kit), and remaining DNA was purified using a spin column. 
DNA was quantified using qPCR (ABI 7900HT) using SYBR green (Applied 
Biosystems). Primers were designed using Primer3 tool (Whitehead Institute for 
Biomedical Research; Cambridge, MA) coding for a series of regions up to 2500 base 
pairs upstream of the transcriptional start site of ABCA1 (Figure 3). This region contains 
the majority of known regulatory elements of ABCA1. 
Table 2: Primer sequences for ChIP. 
Region  Forward (5’-3’) Reverse (5’-3’) 
1 ACCGGTCAAACGCTGTTCTC AGGGCCAGGGCTACAGAAAG 
2 TGAGCCAGGGACTCCACATT TTGGGGGCTGAGCAAACTAA 
3 CCCAGATGCCAACCATTTTC CCCTGGAAGGTGTGTGTGTG 
4 TGGGTTTTGATGATGTCAAACG AGGCTGGGTTCCATCTCTCC 
5 TCGGAAGAAGAGTGCCAACA TTTCCCCTTAGGCGTTTTCC 
6 GGAAAACGCCTAAGGGGAAA AGCAAGTGGATGCTGGGAAC 
7 CCTCCATAAGCACCAGGTGTG GCTTCTTTCTTCCCACCCTTTC 
8 GCCAAATGCTTCATCCAGGT TGGAAGGGAAAGCTCTCTGG 
9 CCAGAGAGCTTTCCCTTCCA GATCCCAGGGTCAGCTCAGA 
 
Percent of input was calculated by 100 x 2(Input – Ct (IP)). 
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Figure 3. 
 
 
 
 
 
Figure 3: ABCA1 promoter mapping for chromatin immunoprecipitation (ChIP). 
qPCR primers (1-9) were designed using Primer3 tool [49] to cover almost the entire -
2500 bp mouse ABCA1 promoter. Amplified fragments (blue) ranged from 178-216 bp 
in length. 
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Luciferase Assay 
 
Plasmid Construction. Mouse ABCA1 promoter DNA was obtained from mouse 
liver genomic DNA (Zyagen; San Diego, CA) using PCR. The reverse primer amplified 
from -11 bp of the ABCA1 transcriptional start site (Figure 5B) and inserted an XhoI 
restriction site. This reverse primer was identical for all fragments. The forward primers 
inserted a BamHI restriction site and amplified regions from -76 to -2500 bp upstream of 
the ABCA1 transcriptional start site. PCR cycling conditions were as follows: 35 cycles 
at 94 °C for 15 seconds, 50 °C for 30 seconds, and 68°C for two minutes with Expand 
High-Fidelity PCR System (Roche). The PCR products were digested with BamHI and 
XhoI (New England Biolabs, Ipswich, MA). The luciferase vector was a TK-Luc plasmid 
[50] (Figure 4) similarly digested with BamHI and XhoI to remove TK promoter and 
linearize. The ABCA1 promoter fragments were then ligated into the luciferase plasmid 
(Figure 5C). The plasmid construct was confirmed by DNA sequencing (Oklahoma State 
University, DNA/Protein Core Facility; Stillwater, OK).  
Transfection & Assay. Purified reporter plasmid constructs for 0.08, 0.25, 1.0, and 
2.5 kilobases of the mouse ABCA1 promoter (0.1 μg) were transiently transfected into 
2.1x104 HEK293T cells (commonly used due to high propensity for transfections) using 
ViaFect transfection reagent (Promega, Madison, WI) at a 3:1 reagent:DNA ratio. Cells 
were cotransfected with 0.05 ng of the NanoLuc pNL-PGK vector (Promega). After 18 
hours transfection time, cells were incubated with 200 μM DADS, 0.1 μM TSA, or 
vehicle (0.1% DMSO) in DMEM (10% FBS, no antibiotics) for six hours before 
assaying. Treatments were diluted in DMSO. Luciferase activity was detected using the 
Nano-Glo Dual-Luciferase Reporter Assay System (Promega, #N1610). Relative 
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Luminescence Units (RLUs) were determined by dividing luciferase luminescence by 
NanoLuc luminescence. To verify the assay, cells were separately transfected with a 
ΔTK-Luc plasmid containing 3 direct repeats of the LXR response element as the 
promoter and treated with LXR agonist T-compound (Sigma, #293754-55-9) at 1 μM for 
18 hours. Luminescence was detected in the same fashion. 
Statistical methods: 
Statistical analyses were performed using a two-tailed t-test for assays involving 
only two groups. To compare differences between more than two groups, one-way 
ANOVA on SAS 9.4 software was used with a post hoc LSD procedure for pairwise 
comparisons. All data were expressed as mean ±SEM. Probability values of p < 0.05 
were considered significant. 
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Figure 4. 
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Figure 4: Map of TK-Luc plasmid used for ABCA1 promoter construct creation. 
The shown plasmid, TK-Luc, contains a thymidine kinase (TK) promoter upstream of the 
luciferase gene. We used BamHI and XhoI to remove this promoter and inserted ABCA1 
promoter fragments instead; thus, the finished plasmid is identical to this map aside from 
this promoter switch [50]. 
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Figure 5. 
A  
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Figure 5: ABCA1 promoter regulatory elements and luciferase constructs. (A) The -
2500 bp ABCA1 promoter has several binding motifs, including the Liver X Receptor 
Response Element (LXRE), multiple Sp1 binding sites, and an AP-1 binding site. (B) The 
entire mouse ABCA1 promoter was isolated from mouse genomic DNA using PCR. The 
reverse primer (R), identical for all fragments, amplified from -11bp of the ABCA1 
transcriptional start site and engineered in an XhoI restriction site (underlined). The 
forward primers (F1-F4) amplified regions from -76 to -2500 bp upstream of the ABCA1 
transcriptional start site, engineering in a BamHI restriction site (underlined). (C) The 
promoter fragments were inserted into a luciferase reporter vector. 
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CHAPTER IV 
 
 
FINDINGS 
Garlic-derived compounds DADS, AM, and SAC increase ABCA1 mRNA 
abundance 
ABCA1 is the main cholesterol efflux transporter in macrophages, responsible for 
loading cholesterol onto high density lipoprotein (HDL). To determine the effects of 
garlic-derived compounds on mRNA expression of ABCA1, qPCR was performed on 
treated murine macrophage RAW 264.7 cells. Maximal effects on ABCA1 mRNA 
expression were observed at six hours (data not shown), so this time point was selected 
for all assays. Analysis revealed an eight-fold increase in mRNA due to treatment with 
DADS, and around a four-fold increase for AM and SAC (Figure 6). Pan-HDAC 
inhibitor TSA also caused a four-fold increase in ABCA1 mRNA.  
At the determined doses of 200 μM DADS, 900 M AM, 2.5 mM SAC, and 0.01 
M TSA, MTT assay for cell viability showed a significantly lower cell viability in SAC-
treated cells after six hours (Figure 7). Due to this effect on SAC-treated cells, we did not 
carry out further gene expression analysis for this compound. 
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The LXR pathway is known to activate not only ABCA1, but also genes such as 
ATP-binding cassette transporter G1 (ABCG1), which encodes a secondary cholesterol 
efflux vehicle [17]. Additionally, AM specifically has been shown to increase cholesterol 
synthesis in human liver cells [36], and HMG Co-A Reductase (HMGCR) is the rate-
controlling enzyme of the mevalonate pathway that produces cholesterol. Treatment of 
RAW 264.7 cells with DADS, AM, or TSA showed no significant differences in ABCG1 
(Figure 8A), and murine liver Hepa 1-6 cells treated with AM showed no significant 
differences in expression of HMGCR (Figure 8B). 
DADS does not increase levels of acetylated histone H3 or H4 in the ABCA1 
promoter 
The present study used chromatin immunoprecipitation assays to examine histone 
modification in nine regions of the 2500 bp ABCA1 promoter (Figure 3). We found no 
significant differences in acetylated histone H3 (Figure 9A) or H4 (9B) in any region of 
the 2500 bp ABCA1 promoter related to treatment with DADS or pan-HDAC inhibitor 
TSA. Although TSA appeared to increase levels of histone H4 in almost every segment 
amplified by qPCR, this trend was not statistically significant. Measures of positive 
control histone H3 (unmodified and equally present in all chromatin) (Figure 9C) and 
negative control IgG (9D) were not significantly different based on treatment with either 
DADS or TSA. 
DADS increases ABCA1 promoter luciferase activity 
In order to determine whether the effect of DADS on putative ABCA1 promoter 
activation would persist in a histone-independent state and whether activation was 
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specific to a certain region of the promoter, four different promoter-fragment/luciferase 
plasmid constructs were created with progressively longer segments of the promoter. 
These circularized plasmids were transiently expressed in HEK293T cells, where 
histones exist naturally but are not associated with the plasmids. 
To verify the assay, a plasmid containing a direct repeat of the LXRE preceding 
the luciferase gene was transfected and treated with LXR agonist T-compound. When 
this plasmid was cotransfected with LXR/RXR (required heterodimer for LXR 
activation), T-compound treatment caused significantly increased luciferase activity 
(Figure 10). LXR/RXR is normally present in HEK293T cells, but cotransfection to 
increase expression was required in this short promoter construct to see increases in 
transcription with T-compound treatment. In further assays using longer ABCA1 
promoter constructs (all but the 0.08 kb construct), T-compound promoter activation was 
seen independent of LXR/RXR cotransfection (data not shown). 
In HEK293T cells transfected with the ABCA1-luciferase plasmids, basal 
promoter activity was increased as promoter size increased (Figure 11). In all promoter 
constructs, six hour treatment with DADS significantly increased luciferase activity 
(Figure 12). Treatment with TSA caused a similar increase.  
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Figure 6. 
 
 
 
 
Figure 6: Effect of six hour garlic compound treatment on ABCA1 mRNA 
expression in RAW 264.7 cells. Cells seeded at 3.7x105 cells/mL were treated with 0.1% 
DMSO (vehicle control), 200 M DADS, 900 M AM, 2.5 mM SAC, or 0.01 M TSA 
for six hours. Total RNA was isolated and reverse transcribed, and ABCA1 expression 
was evaluated by real-time polymerase chain reaction (qPCR). Analysis was done using 
the 2-Ct method, with cyclophilin B as the invariant control. Significance was calculated 
using a one-way ANOVA on SAS software with ⍺=0.05 and a post hoc LSD test. Groups 
that lack a common letter are significantly different. 
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Figure 7. 
 
 
 
Figure 7: Effect of six hour garlic compound treatment on RAW 264.7 cell viability 
as determined by MTT assay. Cells seeded at 3.7x105 cells/mL were treated with 0.1% 
DMSO (vehicle control), 200 M DADS, 900 M AM, 2.5 mM SAC, or 0.01 M TSA 
for four hours, after which 5 mg/ml MTT was added for an additional two hours (six 
hours total treatment length). The plate was read at OD 570.  Significance was calculated 
using a one-way ANOVA on SAS software with ⍺=0.05, and post hoc LSD procedure for 
pairwise comparison. Groups that lack a common letter are significantly different. 
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Figure 8. 
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Figure 8: Effects of garlic compounds on ABCG1 and HMGCR. (A) RAW 264.7 
cells seeded at 3.7x105 cells/mL were treated with 0.1% DMSO, 200 M DADS, 900 M 
AM, or 0.01 M TSA for six hours. (B) Hepa 1-6 cells seeded at 3.7x105 cells/mL were 
treated with 0.1% DMSO or 900 M AM for six hours.  
After treatment, total RNA for each group was isolated and reverse transcribed, and gene 
expression was evaluated by quantitative real-time polymerase chain reaction (qPCR). 
RAW 264.7 cells (A) were analyzed for expression of ABCA1; Hepa 1-6 cells (B) were 
analyzed for expression of HMGCR. Analysis was done using the 2-Ct method, with 
cyclophilin B as the invariant control. Significance was calculated using a one-way 
ANOVA on SAS software and post hoc LSD procedure for pairwise comparison (A) or a 
t-test (B) with ⍺=0.05.  
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Figure 9.  
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Figure 9: Effect of DADS treatment on amount of acetylated histone H3 and H4 in 
mouse ABCA1 promoter in RAW 264.7 cells. After six hour treatment with 200 M 
DADS or 0.01 M TSA, 4x106 RAW 264.7 cells per treatment group were cross-linked 
with formaldehyde and digested with nuclease. Cells were lysed using sonication, and 
lysates incubated with antibodies. After washing and reversing cross-links, purified DNA 
was quantified using qPCR (primers shown in Table 2). Percent of input was calculated 
by 100 x 2(Input – Ct (IP)).  
Figure displays results for acetylated histone H4 (A); acetylated histone H3 (B); total 
histone H3 (positive control) (C); and IgG (negative control) (D). 
Significance was calculated using one-way ANOVA with ⍺=0.05. No significant 
differences based on treatment were found in any region of the promoter for any antibody 
used. 
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Figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Effect of T-compound on DR4X3 plasmid. 0.07 μg DR4X3 plasmid was 
transfected into 2.1x104 HEK293T cells in the presence of RXRα (0.03 μg) and LXRα 
(0.03 μg). Cells were cotransfected with 0.5 ng NanoLuc pNL-PGK vector to normalize 
differences in transfection efficiency. Six hours after transfection, cells were treated with 
1 μM T-compound for 18 hours. Luciferase activity was detected as relative 
luminescence units (RLUs) using the Nano-Glo Dual-Luciferase Reporter Assay System. 
Significance was calculated using a two-tailed t-test with ⍺=0.05. Groups that lack a 
common letter are significantly different. 
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Figure 11. 
 
 
 
 
 
Figure 11: Differing levels of basal luciferase activity based on plasmid size. Purified 
reporter plasmid constructs for 0.08, 0.25, 1.0, and 2.5 kilobases of the mouse ABCA1 
promoter (0.1 μg) were transiently transfected into 2.1x104 HEK293T cells. Cells were 
cotransfected with 0.05 ng of the NanoLuc pNL-PGK vector. After 24 hours, luciferase 
activity was detected using the Nano-Glo Dual-Luciferase Reporter Assay System. 
Relative luciferase activity was determined by dividing luciferase luminescence by 
NanoLuc luminescence. Significance was calculated using one-way ANOVA analysis on 
SAS software with ⍺=0.05, and post hoc LSD procedure for pairwise comparison. 
Groups that lack a common letter are significantly different.  
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Figure 12. 
 
 
 
 
 
 
 
Figure 12: Effect of DADS and TSA on ABCA1 promoter-luciferase plasmids. 
Purified reporter plasmid constructs for 0.08, 0.25, 1.0, and 2.5 kilobases of the mouse 
ABCA1 promoter (0.1 μg) were transiently transfected into 2.1x104 HEK293T cells. 
Cells were cotransfected with 0.05 ng of the NanoLuc pNL-PGK vector. After 18 hours 
transfection time, cells were incubated with 200 μM DADS, 0.1 μM TSA, or vehicle 
(0.1% DMSO) in DMEM (10% FBS) for six hours before assaying. Luciferase activity 
was detected using the Nano-Glo Dual-Luciferase Reporter Assay System. Relative 
Luminescence Units (RLUs) were determined by dividing luciferase luminescence by 
NanoLuc luminescence. Significance was calculated using one-way ANOVA analysis on 
SAS software with ⍺=0.05, and a LSD post hoc procedure for pairwise comparison 
within groups. Groups that lack a common letter (within a given plasmid construct) are 
significantly different. 
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CHAPTER V 
 
 
CONCLUSION 
Changes in mRNA expression due to garlic compound treatment 
In this study, treatment with garlic-derived compounds DADS, AM, and SAC 
increased ABCA1 mRNA expression significantly in RAW 264.7 murine macrophage 
cells. The importance of the role of ABCA1 in cholesterol efflux is highlighted in 
Tangier disease, where a mutation of ABCA1 causes severe cholesterol buildup, 
hepatosplenomegaly, peripheral neuropathy, and increased risk of CVD [13]. Conversely, 
increasing expression of ABCA1 has been linked to an inhibition of atherosclerotic lesion 
progression due to increased reverse cholesterol transport [14]. According to Wang et al. 
[51] increased ABCA1 expression in macrophages improved HDL-c levels, and may 
improve cholesterol efflux to HDL to slow or delay the development of atherosclerosis. 
Due to the potentially antiatherogenic effects of increasing this cholesterol transporter, 
the upregulation of ABCA1 mRNA expression by garlic compounds DADS, AM, and 
SAC may be protective against atherosclerosis.  Associations of garlic supplementation 
with reduced serum cholesterol in human studies support this idea. 
ABCG1 is a secondary cholesterol efflux vehicle present in macrophages. In the present 
study, treatment with DADS, AM, and TSA failed to increase ABCG1 expression. This 
suggests that the increase in ABCA1 expression may not be mediated by the LXR, 
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because LXR activation leads to an increase of ABCG1 [17]. 
Some studies suggest that garlic works to reduce serum cholesterol levels by 
decreasing cholesterol synthesis. In human Hep-G2 cells, AM (0.3 mM-1.3 mM) 
significantly inhibited 3H-acetate incorporation into cholesterol (up to 80%) as well as 
cholesterol secretion into medium (up to 50%) after a four hour treatment period [36]. In 
the present study in murine Hepa 1-6 liver cells, AM did not cause a significantly higher 
mRNA expression of HMG Co-A Reductase, the rate-limiting enzyme in the cholesterol 
synthesis pathway and the main target of cholesterol-reducing medications such as 
atorvastatin (Lipitor) and fluvastatin (Lesecol) [52, 53]. The effects of AM on cholesterol 
synthesis may not be mediated by increasing mRNA transcription of this enzyme; 
HMGCR activity was shown to be reduced in rat hepatocytes treated with allicin and 
ajoene (another byproduct of allicin degradation) [54], and cholesterol synthesis can be 
regulated by post-transcriptional modification of HMGCR [55]. Treatment of Hepa 1-6 
cells with DADS and AM did not result in significantly higher mRNA expression of 
ABCA1 (data not shown).  
Garlic compound effect on cell viability 
In previous studies, garlic compounds have been shown to be cytotoxic or to 
inhibit cell proliferation at high levels. Liao et al [56] found DADS to significantly 
inhibit cell proliferation in human colon cancer SW480 cells at levels from 205-480 μM. 
In the previously mentioned study by Cho et al. testing AM treatment effect on 
cholesterol synthesis, AM caused decreased cell viability at levels above 3.4 mM, 
although the lower levels of 0.3-1.3 mM that reduced cholesterol synthesis and secretion 
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were not found to be significantly detrimental [36]. In the present study at doses of 200 
μM DADS, 900 M AM, and 2.5 mM SAC (doses determined by literature and 
preliminary trials), MTT assay showed significantly lower viability in SAC-treated RAW 
264.7 cells. Although SAC is thought to be up to 30 times less toxic than DADS and 
allicin [57], the levels needed to cause a significant increase in ABCA1 mRNA (2.5 mM) 
were cytotoxic in this study; SAC did not affect ABCA1 mRNA levels at doses below 2.5 
mM (data not shown). Due to this cytotoxic effect, we did not continue further testing 
with SAC. 
Effect of DADS on histone acetylation 
Studies show that DADS specifically may work as a histone deacetylase inhibitor. 
Druesne et al [48] found that in human colon cancer Caco-2 and HT-29 cells, treatment 
with 200 μM DADS for six hours significantly increased acetylated histone in the p21 
promoter, leading to increased transcription and translation. Histone acetylation was 
evaluated by histone extraction and western blotting, and DADS increased acetylation of 
histone H3 in both cell lines and H4 only in Caco-2. A follow-up study using chromatin 
immunoprecipitation in conjunction with PCR confirmed this finding. Zhao et al. [58] 
found that expression of acetylated histone H3 and H4 was significantly increased in 
human acute myeloid leukemia HL-60 cells, and this expression was linked to an increase 
in p21 protein.  
Chromatin immunoprecipitation assays in the present study indicated no 
significant differences in acetylated histone H3 or H4 in any region of the 2500 bp 
ABCA1 promoter related to treatment with DADS or pan-HDAC inhibitor TSA, despite 
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increases in ABCA1 mRNA abundance. The antibodies used to capture acetylated 
histone H3 and H4 were both pan-histone antibodies, meaning they were nonspecific to 
certain lysine residues. Acetylation of certain residues (Ac-H3K9 and Ac-H3K18) has 
specifically been linked to transcriptional upregulation [59, 60], while the acetylation of 
other residues may have other functions such as affecting methylation and DNA repair 
[61]. If the transcriptional upregulation of ABCA1 due to garlic treatment is due to 
acetylation at only one specific lysine site, the effect may not have been large enough to 
have been captured by the pan-antibody.  
Additionally, due to the lack of current research about the specific area of the 
ABCA1 promoter targeted by garlic compounds, the primers we designed covered most 
portions of the 2,500 bp promoter, but not all of it (50-100 bp gaps between primer 
fragments). If an unknown transcription binding motif exists in a region not covered by 
our primers, the effect would not be shown in our results. All of these are possible 
explanations for the lack of increase in acetylated histone due to garlic treatment.  
Although TSA appeared to increase levels of histone H4 in almost every segment 
amplified by qPCR, this trend was not statistically significant. 
DADS increases ABCA1 promoter transcription in transiently transfected plasmids 
DADS (and TSA) significantly increased luciferase activity of all ABCA1 
promoter fragments used regardless of length. Although DADS may be working as an 
HDAC to increase gene expression, transiently transfected plasmids are not associated 
with the chromatin structure. Thus, transcriptional upregulation may not be a direct result 
of histone modification in the ABCA1 promoter and there must be another mechanism to 
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explain these results. Bao et al. found that TSA works in the promoter of SR-B1, another 
cholesterol efflux transporter, by binding to the transcription element Sp1 and/or SRE 
[62]. In that study when luciferase reporter constructs were created using variations of the 
SR-B1 promoter, luciferase activity was significantly higher in segments containing the 
Sp1 and SRE elements than in segments not including these binding regions [62].  
In contrast, all ABCA1 promoter fragments in the current study treated with 
DADS had elevated luciferase activity, even as close to the transcriptional start site as 75 
bp. TSA had the same effect. It is possible that both DADS and TSA activate the LXRE, 
which is included in the 0.08 KB ABCA1-Luciferase construct; however, no studies to 
date have demonstrated a role for either of these compounds in activating the LXRE, and 
other target genes of LXR such as ABCG1 and HMGCR [17] were not affected by 
treatment with DADS, AM, or TSA in qPCR analysis of mRNA abundance.  
Another more viable explanation for this increase in luciferase activity is that both 
DADS and TSA upregulate transcription independent of a specific binding element (i.e. 
increase basal transcription rates). In a similar luciferase reporter construct, Ashburner et 
al. found that inhibition of HDAC activity via TSA treatment increased NF-κB-dependent 
gene expression, whereas HDAC1 and HDAC2 repressed gene expression [63].  
Recently, over 50 non-histone proteins have emerged as substrates for HDAC. 
This group includes transcription factors such as p53, nuclear factor kB (NF-kB), 
hypoxia-inducible factor 1 alpha (HIF-1α), E2F1, and RUNX3 [64]. TSA was shown to 
stabilize acetylation of transcription factor RUNX3 by inhibiting HDAC that normally 
target RUNX3 for degradation through deacetylation [65]. It is possible that DADS 
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and/or TSA work as HDACi to modify either non-histone proteins or histones not found 
in the chromatin scaffolding of the ABCA1 promoter that then cause a transcriptional 
upregulation of ABCA1. 
Limitations 
There are several limitations to the current study. The cell culture model of study 
allows for great manipulation of variables such as dose and time of treatment, and the 
conclusions of cell culture studies are used to design improved future trials in animals 
and humans. However, it can be difficult to directly translate these results into 
conclusions for tissues and whole organisms. Increases in ABCA1 and/or cholesterol 
efflux in vitro may not directly correlate with similar increases in an animal or human. 
Assuming the increase in ABCA1 mRNA is due to a transcriptional upregulation 
is not necessarily the only conclusion; an increase in mRNA stability is another possible 
explanation for the increase seen in qPCR. We did not explore this possibility in the 
current study. 
The ChIP assay was limited by antibody specificity. The pan-acetyl-H3 and pan-
acetyl-H4 antibodies were meant to capture a wide range of histone modifications, but the 
lack of significant differences due to DADS treatment may be due to a specific 
modification not captured by the antibodies. 
In the luciferase assay, both DADS and TSA increased transcription of all 
ABCA1 promoter fragments, and T-compound increased transcription of all but the 
shortest. Vehicle control (DMSO) was used as the baseline; however, no negative control 
was incorporated. Creating another plasmid construct with a gene such as ABCG1 known 
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to not be transcriptionally upregulated by DADS would be helpful in determining 
whether these results are specific to the ABCA1 promoter.  
In conclusion, the presented results demonstrate that garlic compounds DADS, 
AM, and SAC increase mRNA expression of ABCA1 in RAW 264.7 macrophages, and 
this effect may be due to modification of histone proteins not directly associated with the 
ABCA1 promoter chromatin. Future research should involve western blot assay for 
ABCA1 protein to confirm that the increase in mRNA leads to an increase in protein, 
cholesterol efflux assays to confirm that garlic treatment functionally increases efflux, 
and chromatin immunoprecipitation assays using more specific antibodies such as H3K9 
and H3K18 [66]. Luciferase assays should be repeated using constructs for a gene such as 
ABCG1 that should not be transcriptionally upregulated by DADS.
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